Search

Displaying results 5031 - 5040 of 10000 in total
  1. Drug

    NM-702

    go.drugbank.com/drugs/DB05505
    Investigational

    Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis obliterans. … In the USA, a Phase 2 study for intermittent claudication caused by arteriosclerosis obliterans has been successfully completed.

  2. Drug

    Selisistat

    go.drugbank.com/drugs/DB13978
    Investigational

    Enhances p53 acetylation in response to DNA damaging agents. … Selective inhibitor of SIRT1 that does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase family members (IC50 values are 98, 19600, 48700, > 100000 and > 100000 nM for SIRT1, SIRT2, SIRT3

  3. Drug

    Dihydroquinidine barbiturate

    go.drugbank.com/drugs/DB01341
    Experimental

  4. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. … LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases.

  5. Drug

    Alferminogene tadenovec

    go.drugbank.com/drugs/DB05306
    Investigational

    Alferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease … Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration from a standard

  6. Drug

    N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine

    go.drugbank.com/drugs/DB13948
    Experimental

    It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion [L1148]. It was discovered in 2014 at the University of Copenhagen. … 25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine, NBOH-2C-CN
  7. Drug

    N,N'-diphenyl-1,4-phenylenediamine

    go.drugbank.com/drugs/DB14192
    Approved

    Categories: Compounds used in a research, industrial, or household settingSynonyms: N,N'-diphenyl-1,4-phenylenediamine
  8. Drug

    Bentonite

    go.drugbank.com/drugs/DB11306
    ApprovedWithdrawn

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Malacidin B

    go.drugbank.com/drugs/DB14052
    Experimental

    Malacidin B, along with [DB14051], is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria [A33312]. … While structurally similar to other macrocycle drugs like [DB00080] and [DB06087], Malacidin B appears to act via its own distinct mechanism.

  10. Drug

    Malacidin A

    go.drugbank.com/drugs/DB14051
    Experimental

    Malacidin A, along with [DB14052], is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria [A33312]. … While structurally similar to other macrocycle drugs like [DB00080] and [DB06087], Malacidin A appears to act via its own distinct mechanism.